Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB093 for Severe Cerebral Edema in Large Hemispheric Infarction
NCT02864953Phase 3Terminated
- Sponsor
- Remedy Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of glibenclamide in large hemispheric infarction (LHI), cerebral edema, sponsored by Remedy Pharmaceuticals. Started Aug 2018; status: terminated.
02
Drugs
glibenclamide
03
Conditions
large hemispheric infarction (LHI)cerebral edema
Beyond the preview
Go deeper on NCT02864953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864953.